Anti-c-Myc tag FITC

CAT:
270-1F-433-C025
Size:
0.025 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Anti-c-Myc tag FITC - image 1

Anti-c-Myc tag FITC

  • Clone:

    9E10
  • Format:

    FITC
  • Buffer:

    Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
  • References & Citations:

    *Wang X, Campoli M, Ko E, Luo W, Ferrone S: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov;294 (1-2) :23-35., URL: https://www.ncbi.nlm.nih.gov/pubmed/15604013?dopt=, *Hilpert K, Hansen G, Wessner H, Kuttner G, Welfle K, Seifert M, Hohne W: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001 Oct;14 (10) :803-6., URL: https://pubmed.ncbi.nlm.nih.gov/11739900/, *Cermák L, Símová S, Pintzas A, Horejsí V, Andera L: Molecular mechanisms involved in CD43-mediated apoptosis of TF-1 cells. Roles of transcription Daxx expression, and adhesion molecules. J Biol Chem. 2002 Mar 8;277 (10) :7955-61., URL: http://www.ncbi.nlm.nih.gov/pubmed?term=%C4%8Derm%C3%A1k%20l%20%C5%A1%C3%ADmov%C3%A1%20%C5%A1%20pintzas%20a , *Jelínková I, Šafaříková B, Vondálová Blanařová O, Skender B, Hofmanová J, Sova P, Moyer MP, Kozubík A, Kolář Z, Ehrmann J, Hyršlová Vaculová A: Platinum (IV) complex LA-12 exerts higher ability than cisplatin to enhance TRAIL-induced cancer cell apoptosis via stimulation of mitochondrial pathway. Biochem Pharmacol. 2014 Dec 1;92 (3) :415-24., URL: https://pubmed.ncbi.nlm.nih.gov/25285768/, *Siegel J, Brandner G, Hess RD: Cross-reactivity of the monoclonal antibody 9E10 with murine c-MYC. Int J Oncol. 1998 Dec;13 (6) :1259-62., URL: https://pubmed.ncbi.nlm.nih.gov/9824641/, *Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. J Cell Biol. 2008 Aug 11;182 (3) :603-14., URL: http://www.ncbi.nlm.nih.gov/pubmed/18695048?itool=, *Baggio R, Burgstaller P, Hale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW: Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit. 2002 May-Jun;15 (3) :126-34., URL: https://www.ncbi.nlm.nih.gov/pubmed/12203838?dopt=, *Fujiwara K, Poikonen K, Aleman L, Valtavaara M, Saksela K, Mayer BJ: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. Biochemistry. 2002 Oct 22;41 (42) :12729-38., URL: https://www.ncbi.nlm.nih.gov/pubmed/12379115?dopt=, *Svadlenka J, Brazina J, Hanzlikova H, Cermak L, Andera L: Multifunctional adaptor protein Daxx interacts with chromatin-remodelling ATPase Brg1. Biochem Biophys Rep. 2015 Dec 30;5:246-252., URL: https://www.ncbi.nlm.nih.gov/pubmed/28955830, *Ta N, Qu C, Wu H, Zhang D, Sun T, Li Y, Wang J, Wang X, Tang T, Chen Q, Liu L: Mitochondrial outer membrane protein FUNDC2 promotes ferroptosis and contributes to doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2022 Sep 6;119 (36) :e2117396119. , URL: https://pubmed.ncbi.nlm.nih.gov/36037337/, *Pesch T, Bonati L, Kelton W, Parola C, Ehling RA, Csepregi L, Kitamura D, Reddy ST: Molecular design, optimization, and genomic integration of chimeric B cell receptors in murine B cells. Front Immunol. 2019 Nov 14:10:2630., URL: https://pubmed.ncbi.nlm.nih.gov/31798579/, *Oleari R, André V, Lettieri A, Tahir S, Roth L, Paganoni A, Eberini I, Parravicini C, Scagliotti V, Cotellessa L, Bedogni F, De Martini LB, Corridori MV, Gulli S, Augustin HG, Gaston-Massuet C, Hussain K, Cariboni A: A novel SEMA3G mutation in two siblings affected by syndromic GnRH deficiency. Neuroendocrinology 2021;111 (5) :421-441., URL: https://pubmed.ncbi.nlm.nih.gov/32365351/, *Ma J, Jin C, Čančer M, Wang H, Ramachandran M, Yu D: Concurrent expression of HP-NAP enhances antitumor efficacy of oncolytic vaccinia virus but not for Semliki Forest virus. Mol Ther Oncolytics 2021 May 5:21:356-366. doi: 10.1016/j.omto.2021.04.016. eCollection 2021 Jun 25. , URL: https://pubmed.ncbi.nlm.nih.gov/34141872/, *Laurent E, Sieber A, Salzer B, Wachernig A, Seigner J, Lehner M, Geyeregger R, Kratzer B, Jäger U, Kunert R, Pickl WF, Traxlmayr MW: Directed evolution of stabilized monomeric CD19 for monovalent CAR interaction studies and monitoring of CAR-T cell patients. ACS Synth Biol. 2021 May 21;10 (5) :1184-1198. , URL: https://pubmed.ncbi.nlm.nih.gov/33843201/
  • Other References:

    *Persson H, Hennighausen L, Taub R, DeGrado W, Leder P: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984 Aug 17;225 (4663) :687-93. , URL: https://www.ncbi.nlm.nih.gov/pubmed/6431612?dopt=A, *Evan GI et al. 1985. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5:3610-6., URL: , *Spandidos DA et al. 1987. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299-304., URL: , *Prendergast GC. 1999. Mechanisms of apoptosis by c-Myc. Oncogene 18 (19) :2967-2987., URL: , *Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K. 1999. Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253 (1) : 63-77., URL: , *Boxer LM, Dang CV. 2001. Translocations involving c-myc and c-myc function. Oncogene 20 (40) :5595-5610., URL: , *Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21 (21) : 3414-3421., URL:
  • CAS Number:

    9007-83-4